Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
MPW Stock Summary
Top 10 Correlated ETFs
MPW
In the News

The REIT Meltdown Accelerates: Long-Term Investors Should Rejoice
REITs experienced a significant selloff after the Federal Reserve indicated that high interest rates will persist for a while. Despite the market panic, or rather because of it, dividend investors should take this opportunity to buy shares in high-quality yet attractively valued REITs. I discuss why it does not make sense to talk about how "REITs" will do this or that (despite doing it all the time myself), because the average isn't representative.

6 Stellar REITs At Big Discounts To NAV
Many high-quality equity REITs are trading at substantial discounts on price-to-NAV ratios. REITs with good management teams should be able to gain a premium to NAV, but very few are achieving this currently. The amount of new apartment construction poses a risk, but some REITs are trading at unusually cheap price-to-NAV ratios.

Medical Properties Trust Vs. CareTrust REIT: One On The Rise, The Other In Decline
Nursing home landlord CareTrust REIT has outperformed hospital landlord Medical Properties Trust over the past year and 8.5 years. Hospital operators face challenges such as lower revenue growth and rising expenses, while senior care facilities are on the mend. CareTrust REIT's focus on high-quality operators and financial conservatism has led to its outperformance and makes it a better investment option for most investors.

Should You Be Worried About Medical Properties Trust's Liquidity Profile?
Medical Properties Trust (MPW) is expected to face liquidity issues in the coming quarters and has worrisome refinancing needs in the next three years. Despite cutting its dividend in half, MPW's dividend is still unsustainable, and a liquidity crunch is expected if management doesn't take action. MPW has been financing its dividend through asset sales and borrowings, but its cash position will change dramatically in December when a bond matures.

Down 35%, Is Medical Properties Trust a Buy?
This medical office real estate company has been a disappointment, but could it be a smart value play?

Medical Properties Trust: A Disaster Investors Should Have Seen Coming
At $17 in July 2022, MPW was a clear sell. At $6.36 today, it represents a high-risk, high-reward opportunity. Yet investors are more negative on it now than then. 2022 MPW investors did themselves a disservice by ignoring significant red flags around disclosure, debt levels, and comparable companies. P/FFO may seem like a bargain at a little over 4x, but FFO will be pressured significantly moving forward.

Don't Fall for These High-Yield Dividend Stocks in September. Avoid Them Like The Plague.
Medical Properties Trust has halved its dividend, but the clouds remain. Brandywine's big-time dividend is hanging by a thread.

Is Right Now the Perfect Time to Buy This 9.4%-Yielding Dividend Stock?
There's a good case to be made that buying Medical Properties Trust stock right now is like trying to catch a falling knife. However, there are several reasons to be optimistic about the stock's prospects going forward.

Medical Properties Trust: The Right Dividend Call and a Really Awful Look
A long history of supporting dividend payments is a good sign for investors. Dividend cuts are sometimes necessary, but it often pays to attend to the way the cut took place.

The Short-Squeeze Ain't Happening: 3 Stocks to Move On From
Heading into autumn, traders are looking for the next big short-squeeze stock. A common fallacy is that we should turn to former meme and short-squeeze stocks in hopes that lightning will strike twice.
MPW Financial details
MPW Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 2.15 | 2 | 2.36 | 2.62 | 2.58 | |
Net income per share | 2.78 | 0.88 | 0.82 | 1.11 | 1.51 | |
Operating cash flow per share | 1.23 | 1.16 | 1.17 | 1.38 | 1.23 | |
Free cash flow per share | 1.23 | 1.16 | 1.17 | 1.27 | 1.23 | |
Cash per share | 2.25 | 3.42 | 1.04 | 0.78 | 3.22 | |
Book value per share | 12.45 | 16.46 | 13.87 | 14.33 | 14.35 | |
Tangible book value per share | 11.38 | 15 | 11.42 | 11.94 | -8.8 | |
Share holders equity per share | 12.45 | 16.46 | 13.87 | 14.33 | 14.35 | |
Interest debt per share | 10.59 | 17.51 | 17.34 | 22.15 | 18.36 | |
Market cap | 5.88B | 9.02B | 11.53B | 13.91B | 6.67B | |
Enterprise value | 9.12B | 14.68B | 19.99B | 24.9B | 17.78B | |
P/E ratio | 5.78 | 24.06 | 26.73 | 21.21 | 7.39 | |
Price to sales ratio | 7.49 | 10.55 | 9.23 | 9.01 | 4.32 | |
POCF ratio | 13.08 | 18.25 | 18.67 | 17.14 | 9.02 | |
PFCF ratio | 13.08 | 18.25 | 18.67 | 18.65 | 9.02 | |
P/B Ratio | 1.29 | 1.28 | 1.57 | 1.65 | 0.78 | |
PTB ratio | 1.29 | 1.28 | 1.57 | 1.65 | 0.78 | |
EV to sales | 11.62 | 17.19 | 16 | 16.12 | 11.52 | |
Enterprise value over EBITDA | 6.6 | 20.59 | 17.94 | 19.04 | 16.64 | |
EV to operating cash flow | 20.31 | 29.72 | 32.37 | 30.67 | 24.06 | |
EV to free cash flow | 20.31 | 29.72 | 32.37 | 33.37 | 24.06 | |
Earnings yield | 0.17 | 0.04 | 0.04 | 0.05 | 0.14 | |
Free cash flow yield | 0.08 | 0.05 | 0.05 | 0.05 | 0.11 | |
Debt to equity | 0.9 | 1.03 | 1.25 | 1.55 | 1.32 | |
Debt to assets | 0.46 | 0.5 | 0.55 | 0.64 | 0.58 | |
Net debt to EBITDA | 2.35 | 7.95 | 7.59 | 8.4 | 10.4 | |
Current ratio | 4.9 | 7.71 | 4.1 | 4.06 | 2.18 | |
Interest coverage | -2.52 | 2.36 | 0 | 0 | -2.07 | |
Income quality | 0.44 | 1.31 | 1.43 | 1.24 | 0.82 | |
Dividend Yield | 0.06 | 0.05 | 0.05 | 0.05 | 0.1 | |
Payout ratio | 0.36 | 1.1 | 1.32 | 0.98 | 0.77 | |
Sales general and administrative to revenue | 0.1 | 0.11 | 0.11 | 0.09 | 0.1 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.05 | 0.04 | 0.08 | 0.07 | 0.71 | |
Capex to operating cash flow | 0 | 0 | 0 | -0.08 | 0 | |
Capex to revenue | 0 | 0 | 0 | -0.04 | 0 | |
Capex to depreciation | 0 | 0 | 0 | -0.2 | 0 | |
Stock based compensation to revenue | 0.02 | 0.04 | 0.04 | 0.03 | 0.03 | |
Graham number | 27.91 | 18.02 | 15.95 | 18.96 | 22.07 | |
ROIC | 0.06 | 0.04 | 0.05 | 0.04 | 0.03 | |
Return on tangible assets | 0.12 | 0.03 | 0.03 | 0.03 | 0.16 | |
Graham Net | -9.05 | -12.4 | -14.91 | -17.03 | -14.04 | |
Working capital | 849.78M | 2.07B | 1.47B | 1.94B | 768.66M | |
Tangible asset value | 4.16B | 6.41B | 6.04B | 7.03B | -5.27B | |
Net current asset value | -3.22B | -5.07B | -7.54B | -9.5B | -9.65B | |
Invested capital | 0.9 | 1.03 | 1.25 | 1.55 | 1.32 | |
Average receivables | 255.63M | 578.56M | 1.15B | 1.75B | 1.65B | |
Average payables | -434.43M | -67.99M | -53.96M | 0 | 310.66M | |
Average inventory | -58.47M | -30.88M | 0 | 0 | -152.26M | |
Days sales outstanding | 114.78 | 389.02 | 407.6 | 499.39 | 279.64 | |
Days payables outstanding | -1.11K | -1.64K | 0 | 0 | 4.96K | |
Days of inventory on hand | -2.44K | 0 | 0 | 0 | -2.43K | |
Receivables turnover | 3.18 | 0.94 | 0.9 | 0.73 | 1.31 | |
Payables turnover | -0.33 | -0.22 | 0 | 0 | 0.07 | |
Inventory turnover | -0.15 | 0 | 0 | 0 | -0.15 | |
ROE | 0.22 | 0.05 | 0.06 | 0.08 | 0.11 | |
Capex per share | 0 | 0 | 0 | -0.11 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 0.67 | 0.59 | 0.64 | 0.59 | 0.56 | |
Net income per share | 0.32 | 0.37 | -0.23 | 0.05 | -0.07 | |
Operating cash flow per share | 0.27 | 0.36 | 0.3 | 0.23 | 0.13 | |
Free cash flow per share | 0.27 | 0.36 | 0.3 | 0.23 | 0.13 | |
Cash per share | 3.9 | 0.5 | 3.22 | 3.15 | 0.54 | |
Book value per share | 14.8 | 14.74 | 14.37 | 14.11 | 13.89 | |
Tangible book value per share | -8.07 | -7.1 | -8.81 | -7.77 | -8.05 | |
Share holders equity per share | 14.8 | 14.74 | 14.37 | 14.11 | 13.89 | |
Interest debt per share | 18.58 | 16.98 | 18.82 | 17.76 | 17.81 | |
Market cap | 9.14B | 7.1B | 6.66B | 4.92B | 5.54B | |
Enterprise value | 20.1B | 17.07B | 17.77B | 15.2B | 15.61B | |
P/E ratio | 12.06 | 8.01 | -11.88 | 37.49 | -32.95 | |
Price to sales ratio | 22.85 | 20.16 | 17.51 | 14.04 | 16.42 | |
POCF ratio | 55.54 | 33.21 | 36.79 | 36.26 | 72.4 | |
PFCF ratio | 55.54 | 33.21 | 36.79 | 36.26 | 72.4 | |
P/B Ratio | 1.03 | 0.8 | 0.78 | 0.58 | 0.67 | |
PTB ratio | 1.03 | 0.8 | 0.78 | 0.58 | 0.67 | |
EV to sales | 50.22 | 48.43 | 46.71 | 43.4 | 46.27 | |
Enterprise value over EBITDA | 56.39 | 49.93 | 29 | 38.88 | 56.15 | |
EV to operating cash flow | 122.1 | 79.78 | 98.13 | 112.04 | 204 | |
EV to free cash flow | 122.1 | 79.78 | 98.13 | 112.04 | 204 | |
Earnings yield | 0.02 | 0.03 | -0.02 | 0.01 | -0.01 | |
Free cash flow yield | 0.02 | 0.03 | 0.03 | 0.03 | 0.01 | |
Debt to equity | 1.27 | 1.16 | 1.32 | 1.27 | 1.27 | |
Debt to assets | 0.57 | 0.54 | 0.58 | 0.55 | 0.55 | |
Net debt to EBITDA | 30.74 | 29.15 | 18.13 | 26.3 | 36.22 | |
Current ratio | 2.17 | 2.26 | 2.18 | 2.5 | 2.99 | |
Interest coverage | -3.1 | -2.95 | -6.04 | -3.14 | 2.89 | |
Income quality | 0.87 | 0.96 | -1.29 | 4.11 | -1.8 | |
Dividend Yield | 0.02 | 0.02 | 0.03 | 0.04 | 0.03 | |
Payout ratio | 0.92 | 0.78 | -1.24 | 5.38 | -4.13 | |
Sales general and administrative to revenue | 0.1 | 0.11 | 0.11 | 0.12 | 0.11 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.69 | 0.69 | 0.71 | 0.67 | 0.68 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0.03 | 0.03 | 0.04 | 0.03 | 0.02 | |
Graham number | 10.27 | 11.08 | 8.71 | 4.17 | 4.69 | |
ROIC | 0.01 | 0.01 | 0.03 | 0.01 | 0 | |
Return on tangible assets | 0.03 | 0.04 | -0.02 | 0.01 | -0.01 | |
Graham Net | -11.27 | -15.26 | -14.05 | -14.01 | -16.21 | |
Working capital | 684.59M | 739.47M | 768.66M | 934.45M | 985.95M | |
Tangible asset value | -4.83B | -4.25B | -5.27B | -4.65B | -4.82B | |
Net current asset value | -9.61B | -8.88B | -9.65B | -9.65B | -9.41B | |
Invested capital | 1.27 | 1.16 | 1.32 | 1.27 | 1.27 | |
Average receivables | 902.05M | 1.02B | 1.1B | 1.22B | 1.21B | |
Average payables | 281.13M | 281.13M | 310.66M | 608.3M | 297.63M | |
Average inventory | 1.04B | 1.04B | -152.26M | -152.26M | 0 | |
Days sales outstanding | 227.3 | 262.56 | 279.6 | 322.98 | 308.52 | |
Days payables outstanding | 2.39K | 0 | 7.26K | 7.54K | 0 | |
Days of inventory on hand | 8.84K | 0 | -3.56K | 0 | 0 | |
Receivables turnover | 0.4 | 0.34 | 0.32 | 0.28 | 0.29 | |
Payables turnover | 0.04 | 0 | 0.01 | 0.01 | 0 | |
Inventory turnover | 0.01 | 0 | -0.03 | 0 | 0 | |
ROE | 0.02 | 0.03 | -0.02 | 0 | -0.01 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
MPW Frequently Asked Questions
What is Medical Properties Trust, Inc. stock symbol ?
Medical Properties Trust, Inc. is a US stock , located in Birmingham of Al and trading under the symbol MPW
Is Medical Properties Trust, Inc. buy or a sell ?
15 stock analysts have 15 predictions with a medium analyst target price of $19.2. The lowest prediction is $10 and the highest is $27
What is MPW stock prediction ?
With a median analyst target price of $10, 1 stock analysts have made 1 forecasts in last 90 days. $10 is the lowest and $10 is the greatest projection.
What is Medical Properties Trust, Inc. stock quote today ?
Medical Properties Trust, Inc. stock price is $5.279 today.
Is Medical Properties Trust, Inc. stock public?
Yes, Medical Properties Trust, Inc. is a publicly traded company.